KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBITDA Margin (2016 - 2026)

Gilead Sciences filings provide 17 years of EBITDA Margin readings, the most recent being 25.03% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 736.0% to 25.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 34.04%, a 2826.0% increase, with the full-year FY2025 number at 34.04%, up 2826.0% from a year prior.
  • EBITDA Margin hit 25.03% in Q4 2025 for Gilead Sciences, down from 42.82% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 51.77% in Q3 2021 to a low of 64.64% in Q1 2024.
  • Median EBITDA Margin over the past 5 years was 32.4% (2024), compared with a mean of 25.9%.
  • Biggest five-year swings in EBITDA Margin: plummeted -9148bps in 2024 and later surged 9820bps in 2025.
  • Gilead Sciences' EBITDA Margin stood at 12.98% in 2021, then surged by 136bps to 30.68% in 2022, then dropped by -26bps to 22.66% in 2023, then skyrocketed by 43bps to 32.4% in 2024, then fell by -23bps to 25.03% in 2025.
  • The last three reported values for EBITDA Margin were 25.03% (Q4 2025), 42.82% (Q3 2025), and 34.93% (Q2 2025) per Business Quant data.